A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer

Joo Hyuk Sohn, Hye Jin Choi, Joon Chang, Se Kyu Kim, Chang Geal Lee, Kyung Young Chung, Dae Joon Kim, Byoung Chul Cho, Sang Joon Shin, Yong Wha Moon, Joo Hang Kim

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: Irinotecan plus cisplatin has been previously documented to be effective in the treatment of extensive-disease small cell lung cancer (ED-SCLC). This study was undertaken to investigate the efficacy and feasibility of combination chemotherapy of irinotecan and carboplatin in previously untreated ED-SCLC. Patients and methods: From December 2002 to October 2005, 39 patients with previously untreated ED-SCLC were enrolled. Patients were treated with irinotecan (50 mg/m2 IV on days 1, 8, and 15) and carboplatin (target AUC = 5 IV on day 1) every 4 weeks for up to six cycles. Results: Thirty-four patients (87.2%) were male and the median age was 65 years. ECOG performance status was 0-1 in 20 (51.3%) patients and 2 in 19 (48.7%) patients. The median number of chemotherapy cycles was six (range: 1-6 cycles). Thirty-five patients were assessable for response evaluation. The overall response rate was 69.2% (1 CR, 26 PR) under the intent-to-treat analysis. After a median follow-up of 22.7 months, the median time to progression was 6.4 months (95% confidence interval [CI]: 5.7-7.1 months) and median overall survival was 11.0 months (95% CI: 9.9-12.0 months). The estimated 1-year survival rate was 42.5%. In terms of toxicities, Grade 3/4 neutropenia and thrombocytopenia occurred in eight (25.6%) and five (15.4%) patients, respectively. Grade 3/4 non-hematologic toxicities included diarrhea (10.3%), anorexia (7.7%), infection (10.3%), and neutropenic fever (12.8%). There was one treatment-related death due to superimposed infection on the broncho-pleural fistula. Conclusion: The combination chemotherapy of irinotecan and carboplatin was effective and tolerable in previously untreated ED-SCLC patients.

Original languageEnglish
Pages (from-to)365-370
Number of pages6
JournalLung Cancer
Volume54
Issue number3
DOIs
Publication statusPublished - 2006 Dec

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Sohn, J. H., Choi, H. J., Chang, J., Kim, S. K., Lee, C. G., Chung, K. Y., Kim, D. J., Cho, B. C., Shin, S. J., Moon, Y. W., & Kim, J. H. (2006). A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer. Lung Cancer, 54(3), 365-370. https://doi.org/10.1016/j.lungcan.2006.08.014